secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001655759-23-000088
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas Q3 net loss $64M, cash $1B; vepdegestrant Phase 3 on track for 2H 2024
------------------------------------------------------------------------------

- Q3 2023 net loss $64.0M vs $66.2M prior year; revenue $34.6M from collaborations.
- Cash, cash equivalents and marketable securities $1.004B as of Sept 30, 2023; runway into 2026.
- VERITAC-2 Phase 3 trial of vepdegestrant in 2L+ ER+/HER2- breast cancer enrollment ongoing; top-line data 2H 2024.
- Prioritized ARV-766 over bavdegalutamide for Phase 3 in mCRPC based on broader efficacy and superior tolerability.
- Plan to submit two IND/CTA applications for BCL6 (oncology) and LRRK2 (neuroscience) PROTAC degraders by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575923000088/0001655759-23-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575923000088/arvn-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001655759-23-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer